FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:1951-1952 June 21, 2001 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Thalidomide is effective for the treatment of refractory myeloma.¹ Its role in the initial treatment of the disease is under active investigation.^2,3 We report the occurrence of deep venous thrombosis with the use of thalidomide in combination with other active agents in patients with newly diagnosed myeloma.

We initiated a phase 2 trial of treatment with thalidomide, doxorubicin, and dexamethasone in previously untreated patients with symptomatic stage 2 or 3 myeloma at the Memorial Sloan-Kettering Cancer Center. The trial was supported by Celgene, which manufactures thalidomide. Thalidomide was administered orally at a dose of 100 mg for . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., Boccadoro, M., Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111: 3968-3977 [Abstract] [Full Text]  
• Brown, E. N., Herrington, J. D. (2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice 21: 126-137 [Abstract]  
• Kesari, S., Schiff, D., Doherty, L., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O'Neill, A., Drappatz, J., Chen-Plotkin, A. S., Ramakrishna, N., Weiss, S. E., Levy, B., Bradshaw, J., Kracher, J., Laforme, A., Black, P. McL., Folkman, J., Kieran, M., Wen, P. Y. (2007). Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9: 354-363 [Abstract] [Full Text]  
• Michaud, L. B., Karpinski, J. P., Jones, K. L., Espirito, J. (2007). Dietary supplements in patients with cancer: Risks and key concepts, part 1. Am J Health Syst Pharm 64: 369-381 [Abstract] [Full Text]  
• Kang, T. Y., Lowe, C. J., Sekeres, M. A. (2006). Thalidomide Use and Digital Gangrene. JCO 24: 5328-5328 [Full Text]  
• Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., Greipp, P. R. (2006). Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. JCO 24: 431-436 [Abstract] [Full Text]  
• Schwartz, J. D., Sung, M., Schwartz, M., Lehrer, D., Mandeli, J., Liebes, L., Goldenberg, A., Volm, M. (2005). Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-{alpha}2a upon Progression. The Oncologist 10: 718-727 [Abstract] [Full Text]  
• Onozawa, M., Hashino, S., Sogabe, S., Haneda, M., Horimoto, H., Izumiyama, K., Kondo, T., Aldana, L. P., Hamada, K., Asaka, M. (2005). Side Effects and Good Effects from New Chemotherapeutic Agents: CASE 2. Thalidomide-Induced Interstitial Pneumonitis. JCO 23: 2425-2426 [Full Text]  
• Stewart, A. K., Chen, C. I., Howson-Jan, K., White, D., Roy, J., Kovacs, M. J., Shustik, C., Sadura, A., Shepherd, L., Ding, K., Meyer, R. M., Belch, A. R. (2004). Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant. Clin. Cancer Res. 10: 8170-8176 [Abstract] [Full Text]  
• Hassoun, H., Reich, L., Klimek, V. M., Kewalramani, T., Dhodapkar, M., Drake, L., Zimman, R., Hedvat, C. V., Julie, T.-F., Martin, F., Filippa, D. A., Nimer, S. D., Comenzo, R. L. (2004). Doxorubicin and Dexamethasone Followed by Thalidomide and Dexamethasone (AD-TD) as Initial Therapy for Symptomatic Patients with Multiple Myeloma.. ASH ANNUAL MEETING ABSTRACTS 104: 2409-2409 [Abstract]  
• Kyle, R. A., Rajkumar, S. V. (2004). Multiple Myeloma. NEJM 351: 1860-1873 [Full Text]  
• Kumar, S., Witzig, T. E., Rajkumar, S. V. (2004). Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. JCO 22: 2477-2488 [Abstract] [Full Text]  
• Zervas, K., Dimopoulos, M. A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., Mitsouli, Ch., Panagiotidis, P., Korantzis, J., Tzilianos, M., Maniatis, A. (2004). Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 15: 134-138 [Abstract] [Full Text]  
• Dimopoulos, M. A., Anagnostopoulos, A., Weber, D. (2003). Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives. JCO 21: 4444-4454 [Abstract] [Full Text]  
• Tektonidou, M. G, Vlachoyiannopoulos, P. G (2003). Letter to the Editor. Lupus 12: 723-724  
• Anderson, F. A. Jr., Spencer, F. A. (2003). Risk Factors for Venous Thromboembolism. Circulation 107: I-9-16 [Abstract] [Full Text]  
• Trojan, A., Chasse, E., Gay, B., Pichert, G., Taverna, C. (2003). Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol 14: 501-502 [Full Text]  
• Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., Kyle, R. A., Witzig, T. E. (2002). Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma. JCO 20: 4319-4323 [Abstract] [Full Text]  
• Cavo, M., Zamagni, E., Cellini, C., Tosi, P., Cangini, D., Cini, M., Valdre, L., Palareti, G., Masini, L., Tura, S., Baccarani, M. (2002). Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100: 2272-2272 [Full Text]  
• Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Fassas, A., Morris, C., Fink, L., Tricot, G. (2002). Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168-1171 [Abstract] [Full Text]  
• Urbauer, E., Kaufmann, H., Nosslinger, T., Raderer, M., Drach, J. (2002). Thromboembolic events during treatment with thalidomide. Blood 99: 4247-4248 [Full Text]  
• Lee ;, F.-C., Zangari, M. (2002). Second response to lower-dose thalidomide in a patient with multiple myeloma. Blood 99: 4248-4249 [Full Text]  
• Piette, J-C, Sbai, A, Frances, C (2002). Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 11: 67-70  
• Vincent Rajkumar, S., Kyle, R. A. (2001). Thalidomide in the Treatment of Plasma Cell Malignancies. JCO 19: 3593-3595 [Full Text]